Cyclopamine / cycD1/CCND1 Cancer Research Results

Cyc, Cyclopamine: Click to Expand ⟱
Features:
Cyclopamine is a natural steroidal alkaloid derived from the corn lily, Veratrum californicum, which specifically disrupts the Hh signaling pathway.

Cyclopamine — Cyclopamine is a natural steroidal alkaloid Hedgehog pathway antagonist derived from the corn lily Veratrum californicum. It is formally a small-molecule phytochemical / steroidal alkaloid and experimental Smoothened inhibitor. Cyclopamine is best treated as a preclinical tool compound and pharmacologic scaffold rather than a clinically deployed anticancer drug, because systemic translation is constrained by poor solubility, acid instability, limited pharmacokinetics, and developmental toxicity risk.

Primary mechanisms (ranked):

  1. Direct Smoothened inhibition with downstream suppression of canonical Hedgehog signaling and GLI transcriptional output.
  2. Suppression of Hedgehog-dependent cancer cell proliferation, survival, tumor growth, invasion, and metastatic behavior in susceptible models.
  3. Inhibition or reversal of epithelial-mesenchymal transition programs, including reduced GLI1, Snail, Twist, and N-cadherin with increased E-cadherin in context-dependent models.
  4. Reduction of cancer stem-like or tumor-initiating phenotypes where Hedgehog signaling maintains stemness or stromal tumor support.
  5. Secondary noncanonical effects, including Wnt beta-catenin pathway suppression and mitochondrial respiration impairment in some models.

Bioavailability / PK relevance: Cyclopamine has poor aqueous solubility, acid-sensitive conversion to less active products under gastric-like conditions, and suboptimal systemic pharmacokinetics. These constraints explain why clinically used Hedgehog inhibitors are synthetic SMO inhibitors or derivatives rather than cyclopamine itself.

In-vitro vs systemic exposure relevance: Many in-vitro studies use micromolar cyclopamine concentrations, often exceeding what is realistically attractive for systemic exposure with the parent compound. Interpretation should therefore distinguish pathway-probe activity from clinically achievable drug exposure. The compound is concentration-driven, not field-based or device-based.

Clinical evidence status: Preclinical tool compound. Cyclopamine has strong mechanistic and animal-model evidence for Hedgehog pathway inhibition, but it is not an approved anticancer drug and has not become a standard clinical intervention. Clinical translation of this mechanism is represented by approved SMO inhibitors such as vismodegib, sonidegib, and glasdegib, not by cyclopamine itself.

Cyclopamine cancer mechanism table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 SMO Hedgehog GLI axis SMO signaling ↓; GLI1 ↓; PTCH1 output ↓ Developmental and progenitor Hedgehog signaling ↓ R/G Core pathway blockade Most central and most reproducible mechanism. Relevant mainly in tumors with ligand-dependent Hedgehog activity, PTCH loss, SMO activation, or Hedgehog-dependent stromal support.
2 Proliferation and cell cycle control Proliferation ↓; G1 arrest ↑; tumor growth ↓ Normal proliferating progenitor activity may ↓ G Growth suppression Observed across multiple preclinical cancer models, but magnitude depends on Hedgehog dependency and concentration.
3 EMT invasion and metastasis EMT ↓; invasion ↓; migration ↓; metastasis ↓ Context-dependent effects on wound repair and developmental motility programs G Anti-invasive shift Mechanistically linked to GLI1 and EMT transcription factors. Direction aligns with E-cadherin ↑ and N-cadherin, Snail, or Twist ↓ in selected models.
4 Cancer stem-like signaling Self-renewal and tumor-initiating phenotype ↓ Normal stem or progenitor Hedgehog support may ↓ G Stemness suppression Important in tumors where Hedgehog signaling maintains cancer stem-like compartments or therapy-resistant subpopulations.
5 Stromal tumor support Paracrine tumor support ↓ in some models Stromal repair and tissue homeostasis may be altered G Microenvironment modulation Therapeutic leverage is context-dependent. In pancreatic cancer, later clinical experience with Hedgehog inhibition showed that stromal effects can be complex and not uniformly beneficial.
6 Wnt beta-catenin crosstalk Beta-catenin TCF transcription ↓; E-cadherin ↑ Context-dependent epithelial homeostasis effects G Secondary pathway suppression Reported in colorectal cancer models. Best interpreted as downstream or pathway-crosstalk biology rather than the primary drug target.
7 Mitochondrial respiration Aerobic respiration ↓; mitochondrial function ↓ Potential mitochondrial stress in normal cells R/G Secondary bioenergetic stress Reported especially with cyclopamine tartrate. This may contribute to cytotoxicity but is not the canonical defining mechanism.
8 Chemosensitization and radiosensitization Therapy resistance programs ↓ in Hedgehog-dependent contexts Normal-tissue effects uncertain G Adjunctive sensitization potential Preclinical rationale exists through Hedgehog and GLI suppression, but parent cyclopamine is not clinically established as an adjunct.
9 Clinical Translation Constraint In-vitro potency does not reliably translate to systemic therapy Teratogenic and developmental pathway risk is high G Translation limitation Poor solubility, acid instability, PK limitations, and developmental toxicity make cyclopamine mainly a research compound and scaffold for better SMO inhibitors.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
6246- Cyc,    Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
HH↓, TumCP↓, TumCCA↓, TumCI↓, NF-kB↓, MMP2↓, MMP9↓, ERα/ESR1↓, cycD1/CCND1↓,
6247- Cyc,    Sonic Hedgehog Pathway Contributes to Gastric Cancer Cell Growth and Proliferation
- vitro+vivo, GC, MKN45
Shh↓, TumCP↓, TumCCA↓, Apoptosis↓, TumCG↓, cycD1/CCND1↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   TumCCA↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

HH↓, 1,   Shh↓, 1,   TumCG↓, 1,  

Migration ⓘ

MMP2↓, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCP↓, 2,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Hormonal & Nuclear Receptors ⓘ

ERα/ESR1↓, 1,  

Clinical Biomarkers ⓘ

ERα/ESR1↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:66  Target#:73  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page